JPMorgan Chase & Co. set a €55.90 ($65.00) price objective on Gerresheimer (ETR:GXI) in a research note issued to investors on Monday, April 15th, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.
Several other brokerages have also recently commented on GXI. Berenberg Bank set a €81.00 ($94.19) price target on Gerresheimer and gave the stock a buy rating in a research report on Thursday, January 31st. Independent Research set a €72.00 ($83.72) target price on Gerresheimer and gave the company a neutral rating in a report on Friday, April 12th. Deutsche Bank set a €83.00 ($96.51) target price on Gerresheimer and gave the company a buy rating in a report on Tuesday, April 2nd. Credit Suisse Group set a €82.00 ($95.35) target price on Gerresheimer and gave the company a buy rating in a report on Thursday, February 14th. Finally, Goldman Sachs Group set a €65.00 ($75.58) target price on Gerresheimer and gave the company a neutral rating in a report on Friday, March 22nd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. Gerresheimer currently has a consensus rating of Hold and a consensus price target of €69.17 ($80.43).
Shares of GXI traded up €0.90 ($1.05) during trading hours on Monday, hitting €68.95 ($80.17). 101,603 shares of the stock were exchanged, compared to its average volume of 140,925. The company has a debt-to-equity ratio of 68.19, a quick ratio of 0.51 and a current ratio of 0.78. Gerresheimer has a 12-month low of €51.10 ($59.42) and a 12-month high of €80.25 ($93.31). The stock has a market capitalization of $2.20 billion and a price-to-earnings ratio of 12.08.
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Read More: Diversification in Investing
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.